Treating
Neurodegenerative Disease
by Restoring Autophagy
Samsara Therapeutics
Our Mission
Samsara Therapeutics: Treating Neurodegeneration by Improving Autophagy
At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families.
Our Foundation
Founded in 2019 and operating from our corporate headquarters in Boston and our R&D hub in Oxford
Samsara has emerged as a leader in the pursuit of therapeutics for neurodegenerative diseases via the autophagy activation domain. In 2021, Apollo Health Ventures led our $25M Series A given their dedication to investing in companies that pursue innovative approaches to treating age-related diseases.
Based on the scientific achievements driven from our pipeline, Samsara has collected additional endorsement and funding from patient advocacy organizations including
We are committed to providing new opportunities for patients and their families through our drug discovery and development efforts.
Pipeline
Primary indications
Target Protein marker
program
discover
optimization
ind enabling
sponsor
- PD= Parkinson's Disease
- ALS= Amyotrophic Lateral Sclerosis
- CMT= Charcot - Marie - Tooth Disease (type 1A)
Our Leadership
Our senior leadership team
is comprised by a diverse group of seasoned experts who bring a proven track record in pharmaceutical and biotechnological innovation.
Our Portfolio
Innovative Programs Targeting Neurodegeneration
Our portfolio encompasses multiple programs, each designed to tackle various indications of neurodegenerative diseases through autophagy activation:
Our Platform
Phenotypic Screening Platform for Autophagy Related Diseases in Patient Derived Cells
The core of our discovery process is to screen and identify potential autophagy activators, which are then validated in our in house, disease-relevant iPSC (Induced Pluripotent Stem Cells) core across different disease pathologies and patient genotypes. This comprehensive approach enables the efficient advancement of the most promising compounds towards preclinical and clinical development.
